The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Anti-LGR5 Antibody Market Research Report 2025

Global Anti-LGR5 Antibody Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1897609

No of Pages : 107

Ask Your Query
Synopsis
Anti-LGR5 Antibody refers to an antibody that specifically recognizes and binds to the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a cell surface receptor involved in various biological processes, including stem cell maintenance, cell migration, and tumorigenesis. This antibody is used in research to study the function of LGR5 in stem cell biology, development, and diseases such as cancer. It is also employed in diagnostic settings to identify the expression of LGR5 in tissue samples, which can be indicative of certain diseases or conditions.
The global Anti-LGR5 Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The industry trend for-LGR5 Antibody has been growing as research into the role of LGR5 in stem cell regulation and cancer progression gains prominence. The antibody is essential for investigators studying the mechanisms underlying stem cell function and the potential therapeutic targeting of LGR5 in cancer treatment. The development of novel research tools and the increasing focus on precision medicine are driving the demand for high-quality Anti-LGR5 Antibody products. As the understanding of LGR5's functions in health and disease continues to evolve, the industry trend for this antibody is expected to remain strong, with potential applications in both research and clinical settings.
This report aims to provide a comprehensive presentation of the global market for Anti-LGR5 Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-LGR5 Antibody.
Report Scope
The Anti-LGR5 Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-LGR5 Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-LGR5 Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BosterBio
Novus Biologicals
Bioss
GeneTex
Signalway Antibody
Leading Biology
MyBioSource
Thermo Fisher Scientific
ProSci
Biorbyt
R&D Systems
LSBio
StressMarq Biosciences
NSJ Bioreagents
Abnova Corporation
OriGene Technologies
RayBiotech
G Biosciences
ABclonal Technology
Miltenyi Biotec
BioLegend
HUABIO
Biomatik
United States Biological
Merck
AntibodySystem
Sino Biological
Wuhan Fine Biotech
Aviva Systems Biology
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-LGR5 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-LGR5 Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Anti-LGR5 Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-LGR5 Antibody Market Perspective (2019-2030)
2.2 Anti-LGR5 Antibody Growth Trends by Region
2.2.1 Global Anti-LGR5 Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-LGR5 Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-LGR5 Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-LGR5 Antibody Market Dynamics
2.3.1 Anti-LGR5 Antibody Industry Trends
2.3.2 Anti-LGR5 Antibody Market Drivers
2.3.3 Anti-LGR5 Antibody Market Challenges
2.3.4 Anti-LGR5 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-LGR5 Antibody Players by Revenue
3.1.1 Global Top Anti-LGR5 Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-LGR5 Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-LGR5 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-LGR5 Antibody Revenue
3.4 Global Anti-LGR5 Antibody Market Concentration Ratio
3.4.1 Global Anti-LGR5 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-LGR5 Antibody Revenue in 2023
3.5 Anti-LGR5 Antibody Key Players Head office and Area Served
3.6 Key Players Anti-LGR5 Antibody Product Solution and Service
3.7 Date of Enter into Anti-LGR5 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-LGR5 Antibody Breakdown Data by Type
4.1 Global Anti-LGR5 Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-LGR5 Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-LGR5 Antibody Breakdown Data by Application
5.1 Global Anti-LGR5 Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-LGR5 Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-LGR5 Antibody Market Size (2019-2030)
6.2 North America Anti-LGR5 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-LGR5 Antibody Market Size by Country (2019-2024)
6.4 North America Anti-LGR5 Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-LGR5 Antibody Market Size (2019-2030)
7.2 Europe Anti-LGR5 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-LGR5 Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-LGR5 Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-LGR5 Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-LGR5 Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-LGR5 Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-LGR5 Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-LGR5 Antibody Market Size (2019-2030)
9.2 Latin America Anti-LGR5 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-LGR5 Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-LGR5 Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-LGR5 Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-LGR5 Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-LGR5 Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-LGR5 Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BosterBio
11.1.1 BosterBio Company Detail
11.1.2 BosterBio Business Overview
11.1.3 BosterBio Anti-LGR5 Antibody Introduction
11.1.4 BosterBio Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.1.5 BosterBio Recent Development
11.2 Novus Biologicals
11.2.1 Novus Biologicals Company Detail
11.2.2 Novus Biologicals Business Overview
11.2.3 Novus Biologicals Anti-LGR5 Antibody Introduction
11.2.4 Novus Biologicals Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.2.5 Novus Biologicals Recent Development
11.3 Bioss
11.3.1 Bioss Company Detail
11.3.2 Bioss Business Overview
11.3.3 Bioss Anti-LGR5 Antibody Introduction
11.3.4 Bioss Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.3.5 Bioss Recent Development
11.4 GeneTex
11.4.1 GeneTex Company Detail
11.4.2 GeneTex Business Overview
11.4.3 GeneTex Anti-LGR5 Antibody Introduction
11.4.4 GeneTex Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.4.5 GeneTex Recent Development
11.5 Signalway Antibody
11.5.1 Signalway Antibody Company Detail
11.5.2 Signalway Antibody Business Overview
11.5.3 Signalway Antibody Anti-LGR5 Antibody Introduction
11.5.4 Signalway Antibody Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.5.5 Signalway Antibody Recent Development
11.6 Leading Biology
11.6.1 Leading Biology Company Detail
11.6.2 Leading Biology Business Overview
11.6.3 Leading Biology Anti-LGR5 Antibody Introduction
11.6.4 Leading Biology Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.6.5 Leading Biology Recent Development
11.7 MyBioSource
11.7.1 MyBioSource Company Detail
11.7.2 MyBioSource Business Overview
11.7.3 MyBioSource Anti-LGR5 Antibody Introduction
11.7.4 MyBioSource Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.7.5 MyBioSource Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Detail
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Anti-LGR5 Antibody Introduction
11.8.4 Thermo Fisher Scientific Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 ProSci
11.9.1 ProSci Company Detail
11.9.2 ProSci Business Overview
11.9.3 ProSci Anti-LGR5 Antibody Introduction
11.9.4 ProSci Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.9.5 ProSci Recent Development
11.10 Biorbyt
11.10.1 Biorbyt Company Detail
11.10.2 Biorbyt Business Overview
11.10.3 Biorbyt Anti-LGR5 Antibody Introduction
11.10.4 Biorbyt Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.10.5 Biorbyt Recent Development
11.11 R&D Systems
11.11.1 R&D Systems Company Detail
11.11.2 R&D Systems Business Overview
11.11.3 R&D Systems Anti-LGR5 Antibody Introduction
11.11.4 R&D Systems Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.11.5 R&D Systems Recent Development
11.12 LSBio
11.12.1 LSBio Company Detail
11.12.2 LSBio Business Overview
11.12.3 LSBio Anti-LGR5 Antibody Introduction
11.12.4 LSBio Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.12.5 LSBio Recent Development
11.13 StressMarq Biosciences
11.13.1 StressMarq Biosciences Company Detail
11.13.2 StressMarq Biosciences Business Overview
11.13.3 StressMarq Biosciences Anti-LGR5 Antibody Introduction
11.13.4 StressMarq Biosciences Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.13.5 StressMarq Biosciences Recent Development
11.14 NSJ Bioreagents
11.14.1 NSJ Bioreagents Company Detail
11.14.2 NSJ Bioreagents Business Overview
11.14.3 NSJ Bioreagents Anti-LGR5 Antibody Introduction
11.14.4 NSJ Bioreagents Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.14.5 NSJ Bioreagents Recent Development
11.15 Abnova Corporation
11.15.1 Abnova Corporation Company Detail
11.15.2 Abnova Corporation Business Overview
11.15.3 Abnova Corporation Anti-LGR5 Antibody Introduction
11.15.4 Abnova Corporation Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.15.5 Abnova Corporation Recent Development
11.16 OriGene Technologies
11.16.1 OriGene Technologies Company Detail
11.16.2 OriGene Technologies Business Overview
11.16.3 OriGene Technologies Anti-LGR5 Antibody Introduction
11.16.4 OriGene Technologies Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.16.5 OriGene Technologies Recent Development
11.17 RayBiotech
11.17.1 RayBiotech Company Detail
11.17.2 RayBiotech Business Overview
11.17.3 RayBiotech Anti-LGR5 Antibody Introduction
11.17.4 RayBiotech Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.17.5 RayBiotech Recent Development
11.18 G Biosciences
11.18.1 G Biosciences Company Detail
11.18.2 G Biosciences Business Overview
11.18.3 G Biosciences Anti-LGR5 Antibody Introduction
11.18.4 G Biosciences Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.18.5 G Biosciences Recent Development
11.19 ABclonal Technology
11.19.1 ABclonal Technology Company Detail
11.19.2 ABclonal Technology Business Overview
11.19.3 ABclonal Technology Anti-LGR5 Antibody Introduction
11.19.4 ABclonal Technology Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.19.5 ABclonal Technology Recent Development
11.20 Miltenyi Biotec
11.20.1 Miltenyi Biotec Company Detail
11.20.2 Miltenyi Biotec Business Overview
11.20.3 Miltenyi Biotec Anti-LGR5 Antibody Introduction
11.20.4 Miltenyi Biotec Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.20.5 Miltenyi Biotec Recent Development
11.21 BioLegend
11.21.1 BioLegend Company Detail
11.21.2 BioLegend Business Overview
11.21.3 BioLegend Anti-LGR5 Antibody Introduction
11.21.4 BioLegend Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.21.5 BioLegend Recent Development
11.22 HUABIO
11.22.1 HUABIO Company Detail
11.22.2 HUABIO Business Overview
11.22.3 HUABIO Anti-LGR5 Antibody Introduction
11.22.4 HUABIO Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.22.5 HUABIO Recent Development
11.23 Biomatik
11.23.1 Biomatik Company Detail
11.23.2 Biomatik Business Overview
11.23.3 Biomatik Anti-LGR5 Antibody Introduction
11.23.4 Biomatik Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.23.5 Biomatik Recent Development
11.24 United States Biological
11.24.1 United States Biological Company Detail
11.24.2 United States Biological Business Overview
11.24.3 United States Biological Anti-LGR5 Antibody Introduction
11.24.4 United States Biological Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.24.5 United States Biological Recent Development
11.25 Merck
11.25.1 Merck Company Detail
11.25.2 Merck Business Overview
11.25.3 Merck Anti-LGR5 Antibody Introduction
11.25.4 Merck Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.25.5 Merck Recent Development
11.26 AntibodySystem
11.26.1 AntibodySystem Company Detail
11.26.2 AntibodySystem Business Overview
11.26.3 AntibodySystem Anti-LGR5 Antibody Introduction
11.26.4 AntibodySystem Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.26.5 AntibodySystem Recent Development
11.27 Sino Biological
11.27.1 Sino Biological Company Detail
11.27.2 Sino Biological Business Overview
11.27.3 Sino Biological Anti-LGR5 Antibody Introduction
11.27.4 Sino Biological Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.27.5 Sino Biological Recent Development
11.28 Wuhan Fine Biotech
11.28.1 Wuhan Fine Biotech Company Detail
11.28.2 Wuhan Fine Biotech Business Overview
11.28.3 Wuhan Fine Biotech Anti-LGR5 Antibody Introduction
11.28.4 Wuhan Fine Biotech Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.28.5 Wuhan Fine Biotech Recent Development
11.29 Aviva Systems Biology
11.29.1 Aviva Systems Biology Company Detail
11.29.2 Aviva Systems Biology Business Overview
11.29.3 Aviva Systems Biology Anti-LGR5 Antibody Introduction
11.29.4 Aviva Systems Biology Revenue in Anti-LGR5 Antibody Business (2019-2024)
11.29.5 Aviva Systems Biology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock